Response: Commentary: An

Michele Mishto, Guillermo Rodriguez-Hernandez, Jacques Neefjes, Henning Urlaub, Juliane Liepe

Abstract readComment

In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing.Nature communications · 2024
Article
InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides.Scientific data · 2023
Article
Predicting the Success of Fmoc-Based Peptide Synthesis.ACS omega · 2022
Article
Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.Proteomics · 2022
Article
Neo-Splicetopes in Tumor Therapy: A Lost Case?Frontiers in immunology · 2022
Review
Mechanistic diversity in MHC class I antigen recognition.The Biochemical journal · 2021
Review
Commentary: Are There Indeed Spliced Peptides in the Immunopeptidome?Molecular & cellular proteomics : MCP · 2021
Article

4 · The record

Corrections and comments

Commented on by
Is the Immunopeptidome Getting Darker?: A Commentary on the Discussion around Mishto et al., 2019.2021
Comment on
An2019
Comment on
Commentary: An2021

5 · Who and what money

Authors and funding

5 authors.

Michele MishtoCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.

Guillermo Rodriguez-HernandezCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.

Jacques NeefjesDepartment of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center (LUMC), Leiden, Netherlands.

Henning UrlaubMax-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.

Juliane LiepeMax-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.

Funding

Cancer Research UK 29686Cancer Research UK C67500/A29686Department of Health

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsProto-Oncogene Proteins p21(ras)Computer SimulationEpitopesHLA-A AntigensHumansImmunityEpitopesHLA-A AntigensKRAS protein, humanProto-Oncogene Proteins p21(ras)antigen presentationmass spectrometrypeptide splicingproteasometumor immunology

Identifiers

PMID34326838

DOI10.3389/fimmu.2021.679836

PMCPMC8315000

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.